Company intelligence / Profile preview

Meiyou

San Diego, California, United Statesmeiyou.com ↗

Ownership: Private
Development stage: Commercial

Overview

MEI Pharma was a clinical-stage pharmaceutical company focused on developing novel small molecule cancer therapies. Its lead assets included voruciclib, an oral CDK9 inhibitor for hematologic cancers and solid tumors, and ME‑344, a mitochondrial OXPHOS pathway inhibitor. As of July 2024, all clinical development has been discontinued while the company explores strategic alternatives or an orderly wind-down.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeOral cyclin-dependent kinase inhibitorMitochondrial inhibitor
Industry: Biotech

Partnerships

No major current partnerships disclosed; previously engaged in merger discussions with Infinity Pharmaceuticals which failed in late 2023.

Beyond the preview

Go deeper on Meiyou.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meiyou.

Explore the full profile